BioCardia
Biointerventional solutions for heart failure, chronic myocardial ischemia, and acute myocardial infarction

BIOCARDIA NEWS

January 9, 2017
BioCardia to Present at the 9th Annual Biotech Showcase in San Franciscos

December 29, 2016
CardiAMP Pivotal Heart Failure Trial Initiated at Two US Centers

December 23, 2016
BioCardia receives another US Patent covering a method of treating heart attack tissue damage with a patient’s own progenitor cells, providing further protection to Phase III CardiAMP program

December 14, 2016
BioCardia receives US Patent covering a method of treating heart attack tissue damage with a patient’s own progenitor cells, providing further protection to Phase III CardiAMP program

November 18, 2016
BioCardia Chairman of the Board Letter to Shareholders

October 24, 2016
BioCardia Closes Merger with Tiger X Medical, Inc.

August 22, 2016
BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP® Cell Therapy System for the Treatment of Heart Failure

May 23, 2016
BioCardia® receives award from the Maryland Stem Cell Research Fund for CardiAMP cell therapy program for the treatment of ischemic heart failure

May 9, 2016
BioCardia® Receives US Patent Covering a Method of Producing Mesenchymal Stem Cells Using a Single Patient Donor for Both Source Cells and Culture Medium

more news


 

ABOUT BIOCARDIA

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive  biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. 


These programs are enabled by the Company's Helix transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.